Viral Vector Manufacturing Market Size 2025-2029
The viral vector manufacturing market size is forecast to increase by USD 4.1 billion, at a CAGR of 19.3% between 2024 and 2029.
The global viral vector manufacturing market is shaped by the expanding pipeline and regulatory approval of cell and gene therapies. This dynamic creates sustained demand for high-quality clinical and commercial-grade vectors, which are essential for both in vivo and ex vivo treatments. The industry's response includes a strategic shift towards in-house manufacturing and hybrid operational models, as therapy developers seek greater control over supply chains and intellectual property. Key technologies in the broader life sciences, such as those seen in the virus filtration market and in vitro diagnostics contract manufacturing, influence process development. This evolution in operational strategy is critical for managing the intricate production requirements of advanced therapies and securing a competitive edge in a rapidly developing field.Despite strong growth drivers, complex manufacturing processes and persistent scalability issues present formidable challenges. The transition from laboratory-scale methods to commercially viable production is hindered by difficulties in achieving consistent yields and purity. The technical complexity of producing biologics within living cell systems leads to batch-to-batch variability, complicating regulatory submissions and supply chain planning. The industry is actively pursuing solutions through additive manufacturing techniques for bioreactor components and innovations in viral vectors to streamline production. These efforts are crucial for overcoming the inherent bottlenecks that currently temper the market's full growth potential and for making therapies more accessible.
What will be the Size of the Viral Vector Manufacturing Market during the forecast period?
Explore in-depth regional segment analysis with market size data - historical 2019 - 2023 and forecasts 2025-2029 - in the full report.
Request Free Sample
The global viral vector manufacturing market continues to be defined by the interplay between therapeutic innovation and production capacity. The progression of numerous cell and gene therapies through clinical trials necessitates advancements in scalable and reproducible manufacturing of gene delivery systems. This involves optimizing everything from upstream process development with stable producer cell lines to downstream purification processes. As seen in the broader in vitro diagnostics contract manufacturing space, there is a clear move towards platform-based approaches to accelerate development timelines and ensure consistent quality across different therapeutic programs, reflecting a maturing industrial ecosystem.Process intensification and automation are becoming central themes in addressing manufacturing bottlenecks and high costs. The shift toward suspension-based cultures in single-use bioreactors and the implementation of perfusion-based processes are key examples of efforts to increase volumetric productivity. Furthermore, integrating robotics and advanced process analytical technology is critical for minimizing human error and improving process control. These developments, akin to trends in the generative ai in manufacturing sector, are essential for making viral vectors a more reliable and commercially feasible component of the advanced therapies supply chain, enabling broader patient access.
How is this Viral Vector Manufacturing Industry segmented?
The viral vector manufacturing industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2025-2029, as well as historical data from 2019 - 2023 for the following segments.
- Manufacturing type
- In-house manufacturing
- Contract manufacturing
- Application
- Type
- Adeno-associated viral (AAV) vectors
- Lentiviral vectors
- Adenoviral vectors
- Others
- Geography
- North America
- Europe
- Germany
- UK
- France
- Italy
- The Netherlands
- Spain
- Russia
- Asia
- Rest of World (ROW)
By Manufacturing Type Insights
The in-house manufacturing segment is estimated to witness significant growth during the forecast period.
The in-house manufacturing model signifies a strategic, long-term investment by well-capitalized pharmaceutical and biotechnology companies. The primary driver for this approach is the desire for greater control over the entire production lifecycle, including process development, raw material sourcing, and intellectual property protection. This model provides unparalleled flexibility in production scheduling, allowing companies to prioritize their own pipeline assets and adapt quickly to changes in clinical trial timelines or regulatory feedback without depending on external partners' availability.
While this approach requires substantial upfront capital expenditure to build and validate a GMP-compliant facility, it can result in a lower long-term cost of goods sold for companies with a robust pipeline of gene therapy candidates. The primary region for this manufacturing activity contributes to over 33.6% of the market's incremental growth. This model fosters deep integration between research, development, and manufacturing teams, creating a synergistic feedback loop that can accelerate process optimization and the implementation of next-generation production technologies.
Request Free Sample
The In-house manufacturing segment was valued at USD 1.3 billion in 2019 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 33.6% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
Request Free Sample
The North America region, led by the United States, stands as the undisputed global leader in the viral vector manufacturing market. This dominance is the result of a deeply entrenched and synergistic ecosystem that fosters innovation from basic research to commercial-scale production. The region hosts the highest concentration of biotechnology and pharmaceutical companies dedicated to cell and gene therapy development. This creates a persistent and substantial demand for high-quality viral vectors, which is met by a robust network of experienced CDMOs and an increasing number of in-house facilities.
A key driver of the North American market is the significant level of investment from both public and private sources, alongside a proactive regulatory environment. The FDA has established several expedited pathways to facilitate the development and review of promising gene therapies, providing clarity and encouraging continued investment. This strong market position is clear, especially when contextualized by the fact that the second-largest region, Europe, accounts for 29.32% of the market opportunity, highlighting the scale of North America's leadership in this critical sector of advanced medicine.
Market Dynamics
Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The Global Viral Vector Manufacturing Market is experiencing robust growth, primarily driven by the expanding pipeline of cell and gene therapies and the corresponding increase in demand for high-quality vectors. This surge is supported by significant technological innovation in vector production, which is enhancing efficiency and yield. Furthermore, the market is witnessing strategic investments in manufacturing capacity from both established players and new entrants. The expanding regulatory approval for CGT worldwide is providing a clearer path to commercialization, fueling further investment and development. To meet growing demands, there is an accelerated adoption of process automation to streamline production and ensure consistency.Despite the positive outlook, the market faces significant hurdles. The complex manufacturing processes and scalability issues present ongoing challenges, often leading to a prohibitively high cost of goods which can limit patient access. Navigating the evolving and stringent regulatory frameworks also adds another layer of complexity for manufacturers. In response to these challenges and to gain better control over the supply chain, there is a notable strategic shift towards in-house manufacturing by many biopharmaceutical companies. Concurrently, the industry is seeing a diversification of viral vector technologies to overcome the limitations of current platforms.
What are the key market drivers leading to the rise in the adoption of Viral Vector Manufacturing Industry?
- The primary impetus for the global viral vector manufacturing market is the unprecedented expansion of the clinical pipeline for cell and gene therapies and the increasing cadence of regulatory approvals for these transformative treatments.
The expansion of the clinical pipeline for cell and gene therapies, alongside a growing number of regulatory approvals, serves as the principal market driver. Every advancement in the CGT field directly heightens demand for high-quality, clinical-grade viral vector platforms. This symbiotic relationship is moving the industry from speculative potential to commercial realization. Landmark approvals validate therapeutic approaches and establish tangible, recurring demand for vector manufacturing capacity, a factor contributing to over 33.58% of the geographic opportunity. The approval of complex treatments signals to the industry that novel modalities can be commercialized, de-risking investments in other pipeline assets that depend on similar gene delivery systems and necessitating a robust, scalable supply chain.The recognized bottleneck in viral vector supply has catalyzed a massive influx of strategic capital and a proliferation of partnerships aimed at expanding global manufacturing capacity. This driver reflects the market's maturation, with stakeholders making substantial, long-term investments in the required infrastructure. These investments range from building new, large-scale cGMP compliant facilities and acquiring specialized firms to technology licensing and strategic collaborations designed to de-risk supply chains. Major pharmaceutical players now view manufacturing capacity not as a peripheral service but as a critical strategic asset essential for future growth, signaling a broader trend where securing the means of production for advanced therapy medicinal products is paramount.
What are the market trends shaping the Viral Vector Manufacturing Industry?
- A fundamental transformation is reshaping the operational landscape of the global viral vector manufacturing market, marked by a pronounced and strategic migration towards in-house manufacturing capabilities and sophisticated hybrid models.
A fundamental transformation is reshaping the operational landscape, as the industry migrates from a contract development and manufacturing organization (CDMO)-centric model toward in-house manufacturing and hybrid operational models. This strategic rebalancing is driven by a desire for greater supply chain control, intellectual property protection, and long-term cost optimization, a dynamic seen in regions that represent nearly 29.32% of the market opportunity. Rather than fully abandoning CDMOs, companies are blending internal capabilities with external partnerships, leveraging contract manufacturers for early-stage development while building their own facilities for late-stage clinical and commercial supply. This evolution in the computer integrated manufacturing market requires a more sophisticated approach to managing the production of viral vectors.The imperative to increase manufacturing efficiency, reduce production costs, and enhance product quality is catalyzing the rapid adoption of process intensification and automation. Conventional batch-based processes for viral vectors are being replaced by innovative technologies designed to streamline operations and ensure batch-to-batch consistency. Process intensification involves implementing manufacturing technologies that increase volumetric productivity, such as the shift from adherent cultures to suspension-based cultures in single-use bioreactors. The integration of robotics, sophisticated software for process analytical technology, and data analytics is critical for minimizing human error and improving process control, pushing the sector toward a more agile and reliable manufacturing paradigm, mirroring trends in medical device manufacturing outsourcing.
What challenges does the Viral Vector Manufacturing Industry face during its growth?
- The global viral vector manufacturing market confronts a formidable challenge rooted in the inherent biological and technical complexity of its production processes and persistent scalability issues.
The global viral vector manufacturing market confronts a formidable challenge rooted in the inherent biological and technical complexity of its production processes, a factor in regions that make up 27.98% of the global opportunity. Transitioning from small-scale laboratory production to large-scale, commercially viable manufacturing is fraught with difficulties that create significant bottlenecks. Viral vectors are complex biologics produced in living cell systems, making the process susceptible to variability in yield, quality, and purity. A primary issue lies in achieving consistently high titers of functional viral vectors in large-scale bioreactors, as cellular machinery is sensitive to minute changes in process parameters, leading to batch-to-batch variability. A critical and widely acknowledged problem is the separation of full, therapeutically active viral capsids from empty, non-functional ones.A second major challenge is the exceptionally high cost of goods sold (COGS) associated with production, which translates directly into multi-million-dollar price tags for the resulting therapies. This creates significant downstream pressure on reimbursement systems, potentially limiting patient access and capping commercial potential. Key cost drivers include expensive raw materials like GMP-grade plasmids, specialized single-use equipment for bioreactors and purification systems, and the need for highly controlled cleanroom environments. The extensive and sophisticated analytical testing required for quality control at every stage, along with the need for a highly skilled workforce, contributes to a manufacturing cost that can run into millions of dollars per batch, making cost reduction through process innovation a critical industry objective.
Exclusive Customer Landscape
The viral vector manufacturing market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the viral vector manufacturing market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Key Companies & Market Insights
Companies are implementing various strategies, such as strategic alliances, viral vector manufacturing market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
AGC Biologics - The company provides comprehensive, end-to-end services for the development and manufacturing of viral vectors and other advanced biologics. Offerings span from initial process development and scale-up to full cGMP production for preclinical through commercial supply needs. These services leverage expertise in both mammalian and microbial expression systems to deliver customized solutions for a range of therapeutic products, including protein-based therapeutics, mRNA, plasmid DNA, and various cell therapy products, ensuring a complete service portfolio for clients in the advanced therapies sector.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- AGC Biologics
- Aldevron LLC
- Andelyn Biosciences
- Batavia Biosciences BV
- Catalent Inc.
- Charles River Laboratories International Inc.
- Exothera
- FUJIFILM Holdings Corp.
- Genezen
- Lonza Group Ltd.
- Miltenyi Biotec
- Oxford Biomedica Plc
- Sigma Aldrich Chemicals Pvt. Ltd.
- SK Pharmteco
- Takara Bio Inc.
- Thermo Fisher Scientific Inc.
- Virovek Inc
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Viral Vector Manufacturing Market
In June 2024, Thermo Fisher Scientific opened a new sterile drug manufacturing facility in Singapore to enhance its global fill-finish capabilities for vaccines and biologics.In May 2024, Charles River Laboratories International Inc. launched its nAAVigation platform, a standardized, boutique AAV vector platform designed to accelerate gene therapy development timelines.In February 2024, Novo Holdings announced its intention to acquire Catalent Inc. in a multi-billion dollar transaction to significantly boost Novo Nordisk's manufacturing capacity for key drugs and advanced therapies.In January 2024, AGC Biologics announced an expansion of its cell and gene therapy manufacturing services at its facility in Longmont, Colorado, adding new vector suspension and cell therapy capacity.
Research Analyst Overview
The evolution of viral vector platforms is central to the advancement of cell and gene therapies. The development of lentiviral vectors for ex vivo gene therapies involving hematopoietic stem cells, and the use of adeno-associated virus for in vivo gene therapies, exemplify this trend. These platforms are crucial for therapeutic payload delivery in applications from chimeric antigen receptor treatments to oncolytic virus therapies. The foundation of the genetic medicine supply chain depends on robust plasmid dna manufacturing and a constant evaluation of production methods, weighing stable producer cell lines against transient transfection methods. This progress is supported by refined gene editing technology while managing the insertional mutagenesis risk.The transition toward commercial scale production from clinical trial materials drives advancements across the global viral vector manufacturing market. Process intensification is achieved through suspension based cultures in single use bioreactors and perfusion based processes, with the industry anticipating capacity expansion exceeding 25% to meet demand. The downstream purification process is refined using specific chromatography resins and optimized cell culture media within CGMP compliant facilities. Rigorous viral vector characterization and comparability studies are vital, supported by process analytical technology to monitor critical quality attributes like the empty full capsid ratio and host cell protein impurity. Automated manufacturing systems enhance consistency, while the market also evaluates non viral delivery alternatives such as lipid nanoparticles.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Viral Vector Manufacturing Market insights. See full methodology.
|
Market Scope
|
|
Report Coverage
|
Details
|
|
Page number
|
303
|
|
Base year
|
2024
|
|
Historic period
|
2019 - 2023 |
|
Forecast period
|
2025-2029
|
|
Growth momentum & CAGR
|
Accelerating at a CAGR of 19.3%
|
|
Market growth 2024-2029
|
USD 4.1 billion
|
|
Market structure
|
Fragmented
|
|
YoY growth 2024-2029(%)
|
16.2%
|
|
Key countries
|
US, Canada, Mexico, Germany, UK, France, Italy, The Netherlands, Spain, Russia, China, Japan, India, South Korea, Indonesia, Thailand, Singapore, Australia, UAE, Brazil, South Africa, Saudi Arabia, Turkey
|
|
Competitive landscape
|
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
|
Request Free Sample
What are the Key Data Covered in this Viral Vector Manufacturing Market Research and Growth Report?
- CAGR of the Viral Vector Manufacturing industry during the forecast period
- Detailed information on factors that will drive the growth and forecasting between 2024 and 2029
- Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
- Accurate predictions about upcoming growth and trends and changes in consumer behaviour
- Growth of the market across North America, Europe, Asia, Rest of World (ROW)
- Thorough analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the viral vector manufacturing market growth of industry companies
We can help! Our analysts can customize this viral vector manufacturing market research report to meet your requirements.
Get in touch
1 Executive Summary
- 1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Manufacturing Type
- Executive Summary - Chart on Market Segmentation by Application
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- Chart on Overview on criticality of inputs and factors of differentiation
- 2.3 Factors of disruption
- Chart on Overview on factors of disruption
- 2.4 Impact of drivers and challenges
- Chart on Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
- 3 Market Landscape
- 3.1 Market ecosystem
- Chart on Parent Market
- Data Table on - Parent Market
- 3.2 Market characteristics
- Chart on Market characteristics analysis
- 3.3 Value chain analysis
- Chart on Value chain analysis
4 Market Sizing
- 4 Market Sizing
- 4.1 Market definition
- Data Table on Offerings of companies included in the market definition
- 4.2 Market segment analysis
- 4.3 Market size 2024
- 4.4 Market outlook: Forecast for 2024-2029
- Chart on Global - Market size and forecast 2024-2029 ($ billion)
- Data Table on Global - Market size and forecast 2024-2029 ($ billion)
- Chart on Global Market: Year-over-year growth 2024-2029 (%)
- Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
- 5 Historic Market Size
- 5.1 Global Viral Vector Manufacturing Market 2019 - 2023
- Historic Market Size - Data Table on Global Viral Vector Manufacturing Market 2019 - 2023 ($ billion)
- 5.2 Manufacturing Type segment analysis 2019 - 2023
- Historic Market Size - Manufacturing Type Segment 2019 - 2023 ($ billion)
- 5.3 Application segment analysis 2019 - 2023
- Historic Market Size - Application Segment 2019 - 2023 ($ billion)
- 5.4 Type segment analysis 2019 - 2023
- Historic Market Size - Type Segment 2019 - 2023 ($ billion)
- 5.5 Geography segment analysis 2019 - 2023
- Historic Market Size - Geography Segment 2019 - 2023 ($ billion)
- 5.6 Country segment analysis 2019 - 2023
- Historic Market Size - Country Segment 2019 - 2023 ($ billion)
6 Five Forces Analysis
- 6 Five Forces Analysis
- 6.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
- 6.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
- 6.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
- 6.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
- 6.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
- 6.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
- 6.7 Market condition
- Chart on Market condition - Five forces 2024 and 2029
7 Market Segmentation by Manufacturing Type
- 7 Market Segmentation by Manufacturing Type
- 7.1 Market segments
- Chart on Manufacturing Type - Market share 2024-2029 (%)
- Data Table on Manufacturing Type - Market share 2024-2029 (%)
- 7.2 Comparison by Manufacturing Type
- Chart on Comparison by Manufacturing Type
- Data Table on Comparison by Manufacturing Type
- 7.3 In-house manufacturing - Market size and forecast 2024-2029
- Chart on In-house manufacturing - Market size and forecast 2024-2029 ($ billion)
- Data Table on In-house manufacturing - Market size and forecast 2024-2029 ($ billion)
- Chart on In-house manufacturing - Year-over-year growth 2024-2029 (%)
- Data Table on In-house manufacturing - Year-over-year growth 2024-2029 (%)
- 7.4 Contract manufacturing - Market size and forecast 2024-2029
- Chart on Contract manufacturing - Market size and forecast 2024-2029 ($ billion)
- Data Table on Contract manufacturing - Market size and forecast 2024-2029 ($ billion)
- Chart on Contract manufacturing - Year-over-year growth 2024-2029 (%)
- Data Table on Contract manufacturing - Year-over-year growth 2024-2029 (%)
- 7.5 Market opportunity by Manufacturing Type
- Market opportunity by Manufacturing Type ($ billion)
- Data Table on Market opportunity by Manufacturing Type ($ billion)
8 Market Segmentation by Application
- 8 Market Segmentation by Application
- 8.1 Market segments
- Chart on Application - Market share 2024-2029 (%)
- Data Table on Application - Market share 2024-2029 (%)
- 8.2 Comparison by Application
- Chart on Comparison by Application
- Data Table on Comparison by Application
- 8.3 Genetic disorders - Market size and forecast 2024-2029
- Chart on Genetic disorders - Market size and forecast 2024-2029 ($ billion)
- Data Table on Genetic disorders - Market size and forecast 2024-2029 ($ billion)
- Chart on Genetic disorders - Year-over-year growth 2024-2029 (%)
- Data Table on Genetic disorders - Year-over-year growth 2024-2029 (%)
- 8.4 Infectious disease - Market size and forecast 2024-2029
- Chart on Infectious disease - Market size and forecast 2024-2029 ($ billion)
- Data Table on Infectious disease - Market size and forecast 2024-2029 ($ billion)
- Chart on Infectious disease - Year-over-year growth 2024-2029 (%)
- Data Table on Infectious disease - Year-over-year growth 2024-2029 (%)
- 8.5 Cancer - Market size and forecast 2024-2029
- Chart on Cancer - Market size and forecast 2024-2029 ($ billion)
- Data Table on Cancer - Market size and forecast 2024-2029 ($ billion)
- Chart on Cancer - Year-over-year growth 2024-2029 (%)
- Data Table on Cancer - Year-over-year growth 2024-2029 (%)
- 8.6 Neurological disorders - Market size and forecast 2024-2029
- Chart on Neurological disorders - Market size and forecast 2024-2029 ($ billion)
- Data Table on Neurological disorders - Market size and forecast 2024-2029 ($ billion)
- Chart on Neurological disorders - Year-over-year growth 2024-2029 (%)
- Data Table on Neurological disorders - Year-over-year growth 2024-2029 (%)
- 8.7 Others - Market size and forecast 2024-2029
- Chart on Others - Market size and forecast 2024-2029 ($ billion)
- Data Table on Others - Market size and forecast 2024-2029 ($ billion)
- Chart on Others - Year-over-year growth 2024-2029 (%)
- Data Table on Others - Year-over-year growth 2024-2029 (%)
- 8.8 Market opportunity by Application
- Market opportunity by Application ($ billion)
- Data Table on Market opportunity by Application ($ billion)
9 Market Segmentation by Type
- 9 Market Segmentation by Type
- 9.1 Market segments
- Chart on Type - Market share 2024-2029 (%)
- Data Table on Type - Market share 2024-2029 (%)
- 9.2 Comparison by Type
- Chart on Comparison by Type
- Data Table on Comparison by Type
- 9.3 Adeno-associated viral (AAV) vectors - Market size and forecast 2024-2029
- Chart on Adeno-associated viral (AAV) vectors - Market size and forecast 2024-2029 ($ billion)
- Data Table on Adeno-associated viral (AAV) vectors - Market size and forecast 2024-2029 ($ billion)
- Chart on Adeno-associated viral (AAV) vectors - Year-over-year growth 2024-2029 (%)
- Data Table on Adeno-associated viral (AAV) vectors - Year-over-year growth 2024-2029 (%)
- 9.4 Lentiviral vectors - Market size and forecast 2024-2029
- Chart on Lentiviral vectors - Market size and forecast 2024-2029 ($ billion)
- Data Table on Lentiviral vectors - Market size and forecast 2024-2029 ($ billion)
- Chart on Lentiviral vectors - Year-over-year growth 2024-2029 (%)
- Data Table on Lentiviral vectors - Year-over-year growth 2024-2029 (%)
- 9.5 Adenoviral vectors - Market size and forecast 2024-2029
- Chart on Adenoviral vectors - Market size and forecast 2024-2029 ($ billion)
- Data Table on Adenoviral vectors - Market size and forecast 2024-2029 ($ billion)
- Chart on Adenoviral vectors - Year-over-year growth 2024-2029 (%)
- Data Table on Adenoviral vectors - Year-over-year growth 2024-2029 (%)
- 9.6 Others - Market size and forecast 2024-2029
- Chart on Others - Market size and forecast 2024-2029 ($ billion)
- Data Table on Others - Market size and forecast 2024-2029 ($ billion)
- Chart on Others - Year-over-year growth 2024-2029 (%)
- Data Table on Others - Year-over-year growth 2024-2029 (%)
- 9.7 Market opportunity by Type
- Market opportunity by Type ($ billion)
- Data Table on Market opportunity by Type ($ billion)
10 Customer Landscape
- 10 Customer Landscape
- 10.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
11 Geographic Landscape
- 11 Geographic Landscape
- 11.1 Geographic segmentation
- Chart on Market share by geography 2024-2029 (%)
- Data Table on Market share by geography 2024-2029 (%)
- 11.2 Geographic comparison
- Chart on Geographic comparison
- Data Table on Geographic comparison
- 11.3 North America - Market size and forecast 2024-2029
- Chart on North America - Market size and forecast 2024-2029 ($ billion)
- Data Table on North America - Market size and forecast 2024-2029 ($ billion)
- Chart on North America - Year-over-year growth 2024-2029 (%)
- Data Table on North America - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - North America
- Data Table on Regional Comparison - North America
- 11.3.1 US - Market size and forecast 2024-2029
- Chart on US - Market size and forecast 2024-2029 ($ billion)
- Data Table on US - Market size and forecast 2024-2029 ($ billion)
- Chart on US - Year-over-year growth 2024-2029 (%)
- Data Table on US - Year-over-year growth 2024-2029 (%)
- 11.3.2 Canada - Market size and forecast 2024-2029
- Chart on Canada - Market size and forecast 2024-2029 ($ billion)
- Data Table on Canada - Market size and forecast 2024-2029 ($ billion)
- Chart on Canada - Year-over-year growth 2024-2029 (%)
- Data Table on Canada - Year-over-year growth 2024-2029 (%)
- 11.3.3 Mexico - Market size and forecast 2024-2029
- Chart on Mexico - Market size and forecast 2024-2029 ($ billion)
- Data Table on Mexico - Market size and forecast 2024-2029 ($ billion)
- Chart on Mexico - Year-over-year growth 2024-2029 (%)
- Data Table on Mexico - Year-over-year growth 2024-2029 (%)
- 11.4 Europe - Market size and forecast 2024-2029
- Chart on Europe - Market size and forecast 2024-2029 ($ billion)
- Data Table on Europe - Market size and forecast 2024-2029 ($ billion)
- Chart on Europe - Year-over-year growth 2024-2029 (%)
- Data Table on Europe - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Europe
- Data Table on Regional Comparison - Europe
- 11.4.1 Germany - Market size and forecast 2024-2029
- Chart on Germany - Market size and forecast 2024-2029 ($ billion)
- Data Table on Germany - Market size and forecast 2024-2029 ($ billion)
- Chart on Germany - Year-over-year growth 2024-2029 (%)
- Data Table on Germany - Year-over-year growth 2024-2029 (%)
- 11.4.2 UK - Market size and forecast 2024-2029
- Chart on UK - Market size and forecast 2024-2029 ($ billion)
- Data Table on UK - Market size and forecast 2024-2029 ($ billion)
- Chart on UK - Year-over-year growth 2024-2029 (%)
- Data Table on UK - Year-over-year growth 2024-2029 (%)
- 11.4.3 France - Market size and forecast 2024-2029
- Chart on France - Market size and forecast 2024-2029 ($ billion)
- Data Table on France - Market size and forecast 2024-2029 ($ billion)
- Chart on France - Year-over-year growth 2024-2029 (%)
- Data Table on France - Year-over-year growth 2024-2029 (%)
- 11.4.4 Italy - Market size and forecast 2024-2029
- Chart on Italy - Market size and forecast 2024-2029 ($ billion)
- Data Table on Italy - Market size and forecast 2024-2029 ($ billion)
- Chart on Italy - Year-over-year growth 2024-2029 (%)
- Data Table on Italy - Year-over-year growth 2024-2029 (%)
- 11.4.5 The Netherlands - Market size and forecast 2024-2029
- Chart on The Netherlands - Market size and forecast 2024-2029 ($ billion)
- Data Table on The Netherlands - Market size and forecast 2024-2029 ($ billion)
- Chart on The Netherlands - Year-over-year growth 2024-2029 (%)
- Data Table on The Netherlands - Year-over-year growth 2024-2029 (%)
- 11.4.6 Spain - Market size and forecast 2024-2029
- Chart on Spain - Market size and forecast 2024-2029 ($ billion)
- Data Table on Spain - Market size and forecast 2024-2029 ($ billion)
- Chart on Spain - Year-over-year growth 2024-2029 (%)
- Data Table on Spain - Year-over-year growth 2024-2029 (%)
- 11.4.7 Russia - Market size and forecast 2024-2029
- Chart on Russia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Russia - Market size and forecast 2024-2029 ($ billion)
- Chart on Russia - Year-over-year growth 2024-2029 (%)
- Data Table on Russia - Year-over-year growth 2024-2029 (%)
- 11.5 Asia - Market size and forecast 2024-2029
- Chart on Asia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Asia - Market size and forecast 2024-2029 ($ billion)
- Chart on Asia - Year-over-year growth 2024-2029 (%)
- Data Table on Asia - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Asia
- Data Table on Regional Comparison - Asia
- 11.5.1 China - Market size and forecast 2024-2029
- Chart on China - Market size and forecast 2024-2029 ($ billion)
- Data Table on China - Market size and forecast 2024-2029 ($ billion)
- Chart on China - Year-over-year growth 2024-2029 (%)
- Data Table on China - Year-over-year growth 2024-2029 (%)
- 11.5.2 Japan - Market size and forecast 2024-2029
- Chart on Japan - Market size and forecast 2024-2029 ($ billion)
- Data Table on Japan - Market size and forecast 2024-2029 ($ billion)
- Chart on Japan - Year-over-year growth 2024-2029 (%)
- Data Table on Japan - Year-over-year growth 2024-2029 (%)
- 11.5.3 India - Market size and forecast 2024-2029
- Chart on India - Market size and forecast 2024-2029 ($ billion)
- Data Table on India - Market size and forecast 2024-2029 ($ billion)
- Chart on India - Year-over-year growth 2024-2029 (%)
- Data Table on India - Year-over-year growth 2024-2029 (%)
- 11.5.4 South Korea - Market size and forecast 2024-2029
- Chart on South Korea - Market size and forecast 2024-2029 ($ billion)
- Data Table on South Korea - Market size and forecast 2024-2029 ($ billion)
- Chart on South Korea - Year-over-year growth 2024-2029 (%)
- Data Table on South Korea - Year-over-year growth 2024-2029 (%)
- 11.5.5 Indonesia - Market size and forecast 2024-2029
- Chart on Indonesia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Indonesia - Market size and forecast 2024-2029 ($ billion)
- Chart on Indonesia - Year-over-year growth 2024-2029 (%)
- Data Table on Indonesia - Year-over-year growth 2024-2029 (%)
- 11.5.6 Thailand - Market size and forecast 2024-2029
- Chart on Thailand - Market size and forecast 2024-2029 ($ billion)
- Data Table on Thailand - Market size and forecast 2024-2029 ($ billion)
- Chart on Thailand - Year-over-year growth 2024-2029 (%)
- Data Table on Thailand - Year-over-year growth 2024-2029 (%)
- 11.5.7 Singapore - Market size and forecast 2024-2029
- Chart on Singapore - Market size and forecast 2024-2029 ($ billion)
- Data Table on Singapore - Market size and forecast 2024-2029 ($ billion)
- Chart on Singapore - Year-over-year growth 2024-2029 (%)
- Data Table on Singapore - Year-over-year growth 2024-2029 (%)
- 11.6 Rest of World (ROW) - Market size and forecast 2024-2029
- Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
- Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
- Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Rest of World (ROW)
- Data Table on Regional Comparison - Rest of World (ROW)
- 11.6.1 Australia - Market size and forecast 2024-2029
- Chart on Australia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Australia - Market size and forecast 2024-2029 ($ billion)
- Chart on Australia - Year-over-year growth 2024-2029 (%)
- Data Table on Australia - Year-over-year growth 2024-2029 (%)
- 11.6.2 UAE - Market size and forecast 2024-2029
- Chart on UAE - Market size and forecast 2024-2029 ($ billion)
- Data Table on UAE - Market size and forecast 2024-2029 ($ billion)
- Chart on UAE - Year-over-year growth 2024-2029 (%)
- Data Table on UAE - Year-over-year growth 2024-2029 (%)
- 11.6.3 Brazil - Market size and forecast 2024-2029
- Chart on Brazil - Market size and forecast 2024-2029 ($ billion)
- Data Table on Brazil - Market size and forecast 2024-2029 ($ billion)
- Chart on Brazil - Year-over-year growth 2024-2029 (%)
- Data Table on Brazil - Year-over-year growth 2024-2029 (%)
- 11.6.4 South Africa - Market size and forecast 2024-2029
- Chart on South Africa - Market size and forecast 2024-2029 ($ billion)
- Data Table on South Africa - Market size and forecast 2024-2029 ($ billion)
- Chart on South Africa - Year-over-year growth 2024-2029 (%)
- Data Table on South Africa - Year-over-year growth 2024-2029 (%)
- 11.6.5 Saudi Arabia - Market size and forecast 2024-2029
- Chart on Saudi Arabia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Saudi Arabia - Market size and forecast 2024-2029 ($ billion)
- Chart on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- Data Table on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- 11.6.6 Turkey - Market size and forecast 2024-2029
- Chart on Turkey - Market size and forecast 2024-2029 ($ billion)
- Data Table on Turkey - Market size and forecast 2024-2029 ($ billion)
- Chart on Turkey - Year-over-year growth 2024-2029 (%)
- Data Table on Turkey - Year-over-year growth 2024-2029 (%)
- 11.7 Market opportunity by geography
- Market opportunity by geography ($ billion)
- Data Tables on Market opportunity by geography ($ billion)
12 Drivers, Challenges, and Opportunity
- 12 Drivers, Challenges, and Opportunity
- 12.1 Market drivers
- Expanding pipeline and regulatory approval of cell and gene therapies
- Surge in strategic investments and collaborations to expand manufacturing capacity
- Technological innovation in vector production and process optimization
- 12.2 Market challenges
- Complex manufacturing processes and persistent scalability issues
- Prohibitively high cost of goods and stringent reimbursement landscapes
- Evolving and stringent regulatory frameworks for product characterization and safety
- 12.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
- 12.4 Market opportunities
- Strategic shift towards in-house manufacturing and hybrid operational models
- Accelerated adoption of process intensification and automation technologies
- Diversification of viral and non-viral vector technologies
13 Competitive Landscape
- 13 Competitive Landscape
- 13.1 Overview
- 13.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 13.3 Landscape disruption
- Overview on factors of disruption
- 13.4 Industry risks
- Impact of key risks on business
14 Competitive Analysis
- 14 Competitive Analysis
- 14.1 Companies profiled
- 14.2 Company ranking index
- 14.3 Market positioning of companies
- Matrix on companies position and classification
- 14.4 AGC Biologics
- AGC Biologics - Overview
- AGC Biologics - Product / Service
- AGC Biologics - Key offerings
- SWOT
- 14.5 Aldevron LLC
- Aldevron LLC - Overview
- Aldevron LLC - Product / Service
- Aldevron LLC - Key offerings
- SWOT
- 14.6 Batavia Biosciences BV
- Batavia Biosciences BV - Overview
- Batavia Biosciences BV - Product / Service
- Batavia Biosciences BV - Key offerings
- SWOT
- 14.7 Catalent Inc.
- Catalent Inc. - Overview
- Catalent Inc. - Business segments
- Catalent Inc. - Key offerings
- Catalent Inc. - Segment focus
- SWOT
- 14.8 Charles River Laboratories International Inc.
- Charles River Laboratories International Inc. - Overview
- Charles River Laboratories International Inc. - Business segments
- Charles River Laboratories International Inc. - Key offerings
- Charles River Laboratories International Inc. - Segment focus
- SWOT
- 14.9 FUJIFILM Holdings Corp.
- FUJIFILM Holdings Corp. - Overview
- FUJIFILM Holdings Corp. - Business segments
- FUJIFILM Holdings Corp. - Key news
- FUJIFILM Holdings Corp. - Key offerings
- FUJIFILM Holdings Corp. - Segment focus
- SWOT
- 14.10 Genezen
- Genezen - Overview
- Genezen - Product / Service
- Genezen - Key offerings
- SWOT
- 14.11 Lonza Group Ltd.
- Lonza Group Ltd. - Overview
- Lonza Group Ltd. - Business segments
- Lonza Group Ltd. - Key news
- Lonza Group Ltd. - Key offerings
- Lonza Group Ltd. - Segment focus
- SWOT
- 14.12 Miltenyi Biotec
- Miltenyi Biotec - Overview
- Miltenyi Biotec - Product / Service
- Miltenyi Biotec - Key offerings
- SWOT
- 14.13 Oxford Biomedica Plc
- Oxford Biomedica Plc - Overview
- Oxford Biomedica Plc - Product / Service
- Oxford Biomedica Plc - Key offerings
- SWOT
- 14.14 Sigma Aldrich Chemicals Pvt. Ltd.
- Sigma Aldrich Chemicals Pvt. Ltd. - Overview
- Sigma Aldrich Chemicals Pvt. Ltd. - Product / Service
- Sigma Aldrich Chemicals Pvt. Ltd. - Key offerings
- SWOT
- 14.15 SK Pharmteco
- SK Pharmteco - Overview
- SK Pharmteco - Product / Service
- SK Pharmteco - Key offerings
- SWOT
- 14.16 Takara Bio Inc.
- Takara Bio Inc. - Overview
- Takara Bio Inc. - Product / Service
- Takara Bio Inc. - Key offerings
- SWOT
- 14.17 Thermo Fisher Scientific Inc.
- Thermo Fisher Scientific Inc. - Overview
- Thermo Fisher Scientific Inc. - Business segments
- Thermo Fisher Scientific Inc. - Key news
- Thermo Fisher Scientific Inc. - Key offerings
- Thermo Fisher Scientific Inc. - Segment focus
- SWOT
- 14.18 Virovek Inc
- Virovek Inc - Overview
- Virovek Inc - Product / Service
- Virovek Inc - Key offerings
- SWOT
15 Appendix
- 15 Appendix
- 15.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 15.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 15.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 15.4 Research methodology
- 15.5 Data procurement
- 15.6 Data validation
- 15.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 15.8 Data synthesis
- 15.9 360 degree market analysis
- 360 degree market analysis
- 15.10 List of abbreviations
INFORMATION SOURCES
DATA ANALYSIS
REPORT WRITING
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
